Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) EBITDA Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -537.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1,934.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7,261.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,003.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -11,254.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 30,461.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -2,649.00 |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -16,715.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,715.00 |
| Mar 31, 2026 | -8,481.00 |
| Dec 31, 2025 | -24,636.00 |
| Sep 30, 2025 | -20,603.00 |
| Jun 30, 2025 | -37,042.00 |
| Mar 31, 2025 | -46,329.00 |
| Dec 31, 2024 | -53,297.00 |
| Sep 30, 2024 | -73,448.00 |
| Jun 30, 2024 | -35,730.00 |
| Mar 31, 2024 | -273,549.00 |
| Dec 31, 2023 | -9,016.00 |
| Sep 30, 2023 | -7,261.00 |
| Jun 30, 2023 | -10,697.00 |
| Mar 31, 2023 | -24,403.00 |
| Dec 31, 2022 | -14,990.00 |
| Sep 30, 2022 | -22,352.00 |
| Jun 30, 2022 | -10,612.00 |
| Mar 31, 2022 | -8,987.00 |
| Jun 30, 2020 | 409,371.00 |
| Mar 31, 2020 | 4.50 Mn |